ZEO ScientifiX (ZEOX) tops 500 clinicians trained in regenerative biologics Masterclass

Rhea-AI Filing Summary

ZEO ScientifiX, Inc. filed a report describing a business milestone rather than financial results. The company announced that its monthly Masterclass series in regenerative biologics has now trained over 500 clinicians, with each one-day session typically hosting more than 70 attendees at Nova Southeastern University in Florida.

The curriculum focuses on Florida regulatory requirements, evidence-based science, and operational frameworks for responsibly integrating regenerative biologics such as stem cells and extracellular vesicles into medical practice. The next Masterclass is scheduled for April 24 and is limited to clinicians and practice owners.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Clinicians trained: over 500 clinicians Average monthly attendees: over 70 clinicians per session Next Masterclass date: April 24

3 metrics

Clinicians trained over 500 clinicians Cumulative attendees of ZEO Masterclass series

Average monthly attendees over 70 clinicians per session Typical attendance for one-day Masterclass

Next Masterclass date April 24 Upcoming session at Nova Southeastern University’s Center of Innovation

Key Terms

regenerative biologics, extracellular vesicles (EVs), exosome therapeutics, precision longevity medicine, +2 more

6 terms

regenerative biologics medical

"treatment with regenerative biologics, including stem cells and extracellular vesicles (EVs)"

extracellular vesicles (EVs) medical

"regenerative biologics, including stem cells and extracellular vesicles (EVs)"

Extracellular vesicles (EVs) are tiny, membrane-bound packages that cells naturally release into the body carrying bits of protein, genetic material and fat. Think of them as biological postcards that reveal what a cell is doing or can be loaded with therapeutic cargo to deliver drugs. Investors care because EVs can be used as noninvasive disease tests, new drug-delivery platforms, or products with scalable manufacturing and regulatory challenges that affect commercial value.

exosome therapeutics medical

"frameworks in exosome therapeutics and precision longevity medicine"

precision longevity medicine medical

"frameworks in exosome therapeutics and precision longevity medicine"

forward-looking statements regulatory

"Certain statements contained in this press release should be considered forward-looking statements"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

regenerative medicine medical

"clinical education in regenerative medicine innovation"

A field of medical treatments that aims to repair, replace or regenerate damaged tissues and organs using approaches such as cell or gene therapies, engineered tissues, and biologically active materials. It matters to investors because successful regenerative therapies can create entirely new, high-value markets and replace chronic treatments, offering large potential returns but also long development timelines, heavy regulation and high technical risk—like betting on a promising new technology that could either revolutionize care or fail in trials.

Understanding 8-K Material Events →

false 0001557376 0001557376 2026-04-21 2026-04-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of report (Date of earliest event reported): April 21, 2026

ZEO SCIENTIFIX, INC.

(Exact name of registrant as specified in its charter)

Nevada		000-55008		47-4180540
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

3321 College Avenue, Suite 246 Davie, Florida		33314
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (888) 963-7881

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each Class		Trading Symbol		Name of each exchange on which registered
None		N/A		N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

As used in this Current Report on Form 8-K (this “Report”), and unless otherwise indicated, the terms “the Company,” “ZEO,” “we,” “us” and “our” refer to Zeo ScientifiX, Inc.

Item 8.01 Other Events.

On April 21, 2026, ZEO issued a press release announcing it had achieved a significant milestone by successful training over 500 clinicians through its monthly Masterclass series in regenerative biologics treatments.

A copy of the press release is included as Exhibit 99.1 to this Report.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release, dated April 21, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 21, 2026	ZEO SCIENTIFIX, INC.
	By:	/s/ Ian T. Bothwell
		Ian T. Bothwell Chief Executive Officer and Chief Financial Officer

2

Exhibit 99.1

FOR IMMEDIATE RELEASE: APRIL 21, 2026

ZEO ScientifiX Surpasses 500 Physicians Trained in Regenerative Medicine Compliance; Monthly Masterclasses Average 70+ Clinicians

DAVIE, FL — ZEO ScientifiX, Inc. (OTCQB: ZEOX) (“ZEO ScientifiX”), a provider of industry-leading clinical education in regenerative medicine innovation, proudly announces a significant milestone: the successful training of over 500 clinicians through its monthly Masterclass series. ZEO believes that its educational program, held at Nova Southeastern University’s Center of Innovation in Davie, has become a vital resource for physicians nationally navigating the evolving regulatory and scientific landscape of treatment with regenerative biologics, including stem cells and extracellular vesicles (EVs).

The ZEO Masterclass is a rigorous, one-day intensive designed for clinical decision-makers. Since its inception, the program has maintained a consistent and significant reach, notably hosting over 70 attendees every month. The curriculum provides a deep dive into Florida’s specific regulatory requirements, evidence-based science, and the operational frameworks necessary for responsible clinical integration.

Market Demand and Operational Integrity

As the regenerative medicine field faces increased scrutiny, ZEO ScientifiX has prioritized an “education beats promotion” philosophy. The program addresses the narrowing margin for error in the industry by providing direct access to healthcare attorneys, Ph.D. researchers, and veteran clinicians.

“Surpassing the 500-physician mark is a testament to the sheer demand for high-level, compliant education in this space,” said Sean Vega-Stanton, M.S., General Manager of Operations at ZEO ScientifiX. “Every session has reached capacity, which confirms that physicians are moving beyond curiosity and are now committed to understanding how to bring these biologics into their practices the right way. At ZEO ScientifiX, we believe our leadership must extend beyond manufacturing quality to include the empowerment of the physicians using our products.”

Establishing a New Standard of Care

The impact of this training extends beyond the classroom and directly into the clinical setting, where standardized protocols are becoming the benchmark for success.

“Training more than 500 physicians in regenerative biologics represents a defining moment for the field,” said George C. Shapiro, M.D., FACC, Chief Medical Officer of ZEO ScientifiX. “By equipping clinicians with the latest evidence-based frameworks in exosome therapeutics and precision longevity medicine, ZEO ScientifiX is not simply advancing professional education—it is seeking to fundamentally raise the standard of care available to patients across the country.”

Comprehensive Curriculum and Expert Faculty

A cornerstone of the ZEO Masterclass series is the rotation of monthly expert keynote speakers, ensuring that attendees receive the most current perspectives on clinical application and research. Notable past and recurring experts include leaders such as Dr. David Karli and Dr. Faryal Farooqui, who provide specialized insights into the practical use of regenerative therapies.

The core Masterclass faculty includes:

● Sean Vega-Stanton, M.S. (General Manager of Operations)

● Edgar J. Aseby, Esq. (Healthcare Attorney, Regulatory & Compliance)

● Michael Bellio, Ph.D. (VP of Research & Manufacturing)

● George Shapiro, M.D., FACC (Chief Medical Officer)

● Karlista Maroney (Director of Growth Strategy)

● Tami Banno (Director of Practice Development)

● Bob Smoley (Board Advisor)

Attendees participate in sessions covering ethical sourcing, manufacturing quality, risk mitigation, and turn-key practice solutions, concluding with a tour of the ZEO ScientifiX research and lab facilities.

Upcoming Opportunities

ZEO ScientifiX continues its commitment to physician excellence with the next Masterclass scheduled for April 24 at Nova Southeastern University’s Center of Innovation. Registration is limited to clinicians and practice owners to ensure an environment focused on clinical and operational integrity.

About ZEO ScientifiX, Inc.

ZEO ScientifiX, Inc. (OTCQB: ZEOX) is an SEC-reporting, clinical-stage biopharmaceutical company focused on the research, development, and manufacturing of regenerative biologics. Operating out of Nova Southeastern University’s Center of Collaborative Research, the Company translates emerging science into scalable clinical solutions. For more information, visit https://zeoscientifix.com.

2

Forward-Looking Statements

Certain statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Actual results could vary dramatically. ZEO has no intention and specifically disclaims any duty to update the information in this press release.

Media Contact:

Karlista Maroney

ZEO ScientifiX, Inc.

Karlista@zeoscientifix.com

3

FAQ

What did ZEOX disclose in its latest 8-K filing?

ZEO ScientifiX (ZEOX) reported a business milestone, not new financial results. The company highlighted that its regenerative medicine Masterclass series has trained over 500 clinicians and consistently attracts more than 70 attendees per monthly session in Florida.

How many clinicians has ZEO ScientifiX (ZEOX) trained through its Masterclass?

ZEO ScientifiX states it has successfully trained over 500 clinicians through its monthly Masterclass series. These one-day programs focus on regenerative biologics, combining regulatory education, evidence-based science, and operational guidance for safely integrating these treatments into medical practices.

What is the focus of ZEOX’s regenerative medicine Masterclass program?

The ZEO ScientifiX Masterclass emphasizes compliant, evidence-based use of regenerative biologics. It covers Florida-specific regulatory requirements, scientific frameworks around stem cells and extracellular vesicles, and practical operational processes to help clinicians implement these therapies responsibly in their practices.

Where does ZEO ScientifiX (ZEOX) hold its Masterclass sessions?

ZEO ScientifiX holds its monthly Masterclass at Nova Southeastern University’s Center of Innovation in Davie, Florida. The location supports both classroom instruction and tours of the company’s research and laboratory facilities, reinforcing the educational and scientific nature of the program.

How many attendees do ZEOX Masterclass sessions typically attract?

According to the disclosure, each ZEO ScientifiX Masterclass has maintained strong demand, with more than 70 attendees every month. Sessions reach capacity and are limited to clinicians and practice owners to preserve a focused environment on clinical and operational integrity.

When is the next ZEO ScientifiX (ZEOX) Masterclass scheduled?

The next ZEO ScientifiX Masterclass is scheduled for April 24 at Nova Southeastern University’s Center of Innovation. Registration is restricted to clinicians and practice owners so the event remains centered on clinical decision-making, regulatory compliance, and operational best practices in regenerative biologics.

Filing Exhibits & Attachments

4 documents

Press Releases

• EX-99.1 EXHIBIT 99.1 21.4 KB

Other Documents

• EX-101 XBRL SCHEMA FILE 2.9 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB